People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Agilis Biotherapeutics, Inc. | — | Biotechnology | Series A | $25.7M | $458.0M | 2016 |
Mark J. Pykett at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark J. Pykett on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Arthur J. Tzianabos | 1 | 2 |
| G. Houston Hall | 1 | 1 |
| Alexander M. Seaver | 1 | 1 |
| Adrian Z. Stecyk | 1 | 1 |
| Robert J. Hardie | 1 | 1 |
| Ian J. Ratcliffe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.